Coherus BioSciences (CHRS) Competitors

Compugen (NASDAQ:CGEN) and Coherus BioSciences (NASDAQ:CHRS) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, profitability, institutional ownership, community ranking, analyst recommendations, dividends, media sentiment and earnings.

Do analysts recommend CGEN or CHRS?

Compugen currently has a consensus target price of $4.00, suggesting a potential upside of 183.69%. Coherus BioSciences has a consensus target price of $6.13, suggesting a potential upside of 723.25%. Given Coherus BioSciences' higher probable upside, analysts clearly believe Coherus BioSciences is more favorable than Compugen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Compugen	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
Coherus BioSciences	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75

Which has better valuation & earnings, CGEN or CHRS?

Compugen has higher earnings, but lower revenue than Coherus BioSciences. Coherus BioSciences is trading at a lower price-to-earnings ratio than Compugen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Compugen	$33.46M	3.76	-$18.75M	$0.02	70.50
Coherus BioSciences	$257.24M	0.33	-$237.89M	-$0.08	-9.30

Which has more risk and volatility, CGEN or CHRS?

Compugen has a beta of 2.64, indicating that its stock price is 164% more volatile than the S&P 500. Comparatively, Coherus BioSciences has a beta of 0.69, indicating that its stock price is 31% less volatile than the S&P 500.

Is CGEN or CHRS more profitable?

Compugen has a net margin of 2.67% compared to Coherus BioSciences' net margin of -0.15%. Compugen's return on equity of 2.62% beat Coherus BioSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Compugen	2.67%	2.62%	1.36%
Coherus BioSciences	-0.15%	N/A	-24.44%

Does the media favor CGEN or CHRS?

In the previous week, Compugen had 11 more articles in the media than Coherus BioSciences. MarketBeat recorded 14 mentions for Compugen and 3 mentions for Coherus BioSciences. Coherus BioSciences' average media sentiment score of 0.66 beat Compugen's score of 0.31 indicating that Coherus BioSciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Compugen	2 Very Positive mention(s)	4 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Coherus BioSciences	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Does the MarketBeat Community believe in CGEN or CHRS?

Coherus BioSciences received 137 more outperform votes than Compugen when rated by MarketBeat users. Likewise, 65.15% of users gave Coherus BioSciences an outperform vote while only 64.30% of users gave Compugen an outperform vote.

Company	Underperform	Outperform
Compugen	Outperform Votes 308 64.30%	Underperform Votes 171 35.70%
Coherus BioSciences	Outperform Votes 445 65.15%	Underperform Votes 238 34.85%

Do insiders & institutionals believe in CGEN or CHRS?

12.2% of Compugen shares are owned by institutional investors. Comparatively, 72.8% of Coherus BioSciences shares are owned by institutional investors. 9.5% of Compugen shares are owned by insiders. Comparatively, 7.6% of Coherus BioSciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Compugen beats Coherus BioSciences on 11 of the 18 factors compared between the two stocks.